PPD and partner Shin Nippon Biomedical Laboratories have hit the ground running with their Japanese joint venture, closing a deal that will see them join forces in the country's growing market for clinical trials.
WuXi PharmaTech, China's largest CRO, is positioning itself to cash in on the fervor over new immunotherapies for cancer, planning to build a U.S. facility devoted to manufacturing the newfangled cell therapies. Read more >>
CRO giant Icon dialed up its fourth-quarter revenue on the way to a big year, forecasting another leap in 2015. Read more >>
POPULAR COMMENT THREADS
Contract drug developer AMRI is closing down a U.K. manufacturing operation as part of its across-the-board change in strategy, an effort to get back to growth after a rough string of quarters.
Catalent doubled its capacity at a Kentucky manufacturing facility, wrapping up a $52 million project with plans to add about 140 new workers.
Quintiles is further entrenching itself in Latin America, striking a deep-rooted alliance with a research site in Buenos Aires to widen its global network of trusted partners.
Swedish contract drug developer Recipharm has signed a deal with Virginia's Synthonics, investing in the biotech and lending its expertise in the development of new compounds.
Iris Pharma and Oculos Clinical Research, two CROs focused on the eye, have inked a strategic alliance to boost their profiles in the contracting world.
U.S. contractor Aptuit has signed a deal with Italy's Axxam to team up on early-stage R&D services, pooling their resources to better compete for projects.
From Our Sister Sites
Democrats and Republicans just agreed to send "fast track" Trade Promotion Authority legislation to the Senate for a vote. Granting the president fast-track authority allows Congress to vote on free trade agreements on a yes, no basis; if passed, Congress would not have the authority to make amendments to the agreements.
Thoratec touted clinical trial data presented at an International Society for Heart and Lung Transplantation meeting in Nice, France, showing that advanced heart failure patients who receive ambulatory--or outpatient--care are better off using its HeartMate II left ventricular assist device than receiving optimal medical management.